Our study validated these findings, as K–M analysis showed lower survival rates and higher recurrence rates in PCa patients with lower serum ACSL4 levels, suggesting that ACSL4 may serve as a prognostic indicator. The gene discussed is ACSL4; the disease is posterior cortical atrophy.